RSV Vaccination for Elderly Adults: A One-Time Dose, Not Yearly
RSV vaccination for elderly adults is NOT given yearly—it is a single lifetime dose. 1
Current Vaccination Recommendations
Based on the most recent 2024 ACIP guidelines, the RSV vaccine schedule is straightforward:
Who Should Receive RSV Vaccine
All adults ≥75 years old should receive a single dose of RSV vaccine 1
Adults aged 60-74 years should receive a single dose if they have any of these high-risk conditions:
- Chronic cardiovascular disease
- Chronic lung/respiratory disease (COPD, asthma)
- End-stage renal disease
- Diabetes mellitus
- Neurologic/neuromuscular conditions
- Chronic liver disease
- Chronic hematologic conditions
- Severe obesity
- Moderate to severe immunocompromise
- Residence in a nursing home 1
Critical Point: No Repeat Dosing
Adults who have previously received RSV vaccine should NOT receive another dose. 1 This is explicitly stated in the guidelines and represents a fundamental difference from annual influenza vaccination.
Why RSV Occurs Annually But Vaccination Doesn't
While RSV infection does occur annually in elderly populations during fall and winter seasons 1, the vaccine provides durable protection:
- RSVPreF3 (Arexvy): Efficacy maintained for at least 3 seasons 2
- RSVpreF (Abrysvo): Efficacy maintained for at least 2 seasons 2
- mRNA-1345 (mResvia): Recently approved with ongoing monitoring 1
The epidemiology shows RSV affects 3-7% of healthy elderly and 4-10% of high-risk adults annually 3, with substantial morbidity including 11.0% in-hospital mortality 4. However, the current vaccine formulations provide multi-season protection, eliminating the need for annual revaccination.
Available Vaccines (Choose Any One)
Three FDA-approved options are available:
- Arexvy (GSK)
- Abrysvo (Pfizer)
- mResvia (Moderna) 1
Common Pitfall to Avoid
Do not confuse RSV vaccination with influenza vaccination. The annual nature of RSV disease does not translate to annual vaccination requirements. Providers should verify vaccination history before administering RSV vaccine, as repeat dosing is not recommended and may expose patients to unnecessary adverse events without additional benefit 1.
The 2024 ACIP update specifically moved away from shared clinical decision-making to clear age- and risk-based recommendations to maximize coverage among those most likely to benefit while reducing implementation barriers 1.